Ionis Pharmaceuticals reported positive topline outcomes from two pivotal Phase 3 studies (CORE and CORE2) evaluating olezarsen (Tryngolza) in patients with severe hypertriglyceridemia (sHTG). The drug induced significant triglyceride reductions of up to 72% and an 85% decrease in acute pancreatitis events compared to placebo, with a favorable safety profile. These data support Ionis’ plan to pursue FDA label expansion for sHTG, potentially positioning Tryngolza in a multibillion-dollar market. Analysts acknowledge the drug’s robust efficacy but caution risks remain.